灵康药业
(603669)
| 流通市值：30.94亿 | | | 总市值：30.94亿 |
| 流通股本：7.21亿 | | | 总股本：7.21亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 76,861,627.55 | 196,831,359.94 | 150,665,541.41 | 112,920,840.32 |
| 营业收入 | 76,861,627.55 | 196,831,359.94 | 150,665,541.41 | 112,920,840.32 |
| 二、营业总成本 | 94,759,740.05 | 353,767,840.88 | 255,792,111.55 | 181,133,436.74 |
| 营业成本 | 33,008,973.81 | 104,966,744.13 | 79,250,028.36 | 57,421,032.06 |
| 税金及附加 | 660,144.31 | 5,074,830.75 | 3,137,158.44 | 2,366,410.4 |
| 销售费用 | 38,117,162.41 | 120,336,536.58 | 89,028,693.86 | 67,154,711.88 |
| 管理费用 | 18,533,544.17 | 93,780,990.66 | 62,718,810.45 | 40,615,541.75 |
| 研发费用 | 4,772,080.07 | 29,124,769.54 | 21,226,696.58 | 13,301,203.59 |
| 财务费用 | -332,164.72 | 483,969.22 | 430,723.86 | 274,537.06 |
| 其中:利息费用 | 162,796.89 | 3,709,839.82 | 2,944,346.85 | 2,016,438.17 |
| 其中:利息收入 | 510,053.48 | 3,308,542.32 | 2,582,484.66 | 1,786,625.61 |
| 加:公允价值变动收益 | -2,838,771.23 | -10,717,857.79 | -8,600,627.79 | -2,910,964 |
| 加:投资收益 | -3,417,704.43 | -3,816,654.81 | -3,247,612.96 | -2,147,846.16 |
| 资产处置收益 | - | 83,625.67 | 86,342.29 | 86,342.29 |
| 资产减值损失(新) | -24,702.83 | -7,687,473.26 | -1,989,226.07 | -210,035.56 |
| 信用减值损失(新) | 805,413.53 | -10,053,229.8 | -8,659,574.01 | -625,724.21 |
| 其他收益 | 6,165,670.4 | 40,147,358.75 | 33,544,142.03 | 6,256,567.69 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -17,208,207.06 | -148,980,712.18 | -93,993,126.65 | -67,764,256.37 |
| 加:营业外收入 | 1,098,166.75 | 214,809.05 | 214,809.05 | 214,808.71 |
| 减:营业外支出 | 75,230.79 | 2,188,793.88 | 2,042,525.38 | 1,267,968.64 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -16,185,271.1 | -150,954,697.01 | -95,820,842.98 | -68,817,416.3 |
| 减:所得税费用 | -143,764.96 | 540,838.42 | 761,657.87 | 903,921.06 |
| 六、净利润 | -16,041,506.14 | -151,495,535.43 | -96,582,500.85 | -69,721,337.36 |
| 持续经营净利润 | -16,041,506.14 | -151,495,535.43 | -96,582,500.85 | -69,721,337.36 |
| 归属于母公司股东的净利润 | -16,041,506.14 | -151,495,535.43 | -96,582,500.85 | -69,721,337.36 |
| (一)基本每股收益 | -0.02 | -0.21 | -0.13 | -0.1 |
| (二)稀释每股收益 | -0.02 | -0.21 | -0.13 | -0.1 |
| 九、综合收益总额 | -16,041,506.14 | -151,495,535.43 | -96,582,500.85 | -69,721,337.36 |
| 归属于母公司股东的综合收益总额 | -16,041,506.14 | -151,495,535.43 | -96,582,500.85 | -69,721,337.36 |
| 公告日期 | 2024-04-20 | 2024-04-20 | 2023-10-21 | 2023-08-26 |
| 审计意见(境内) | | 标准无保留意见 | | |